HCV therapy continues to improve

Hepatitis C (HCV) therapy has never been better. The latest data show sustained viral response rates (SVR) of 96 percent across the general population, while tweaks to existing regimens and new agents promise to bring SVRs closer to 100 percent. A panel of experts discussed the prospects for new HCV treatments during an AASLD symposium at DDW 2016.

Experts examine access and cost issues of GI drugs

A shift has occurred in the treatment costs of inflammatory bowel disease and other GI conditions. Historically, the highest costs associated with treatment were related to hospitalizations. Today, much of the cost can be attributed to the increased expense of prescription drugs, said Akbar K. Waljee, MD, one of four speakers to discuss the cost and cost-effectiveness of various GI drugs during an AGA symposium at DDW 2016.